Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients

Phase 1

Completed

• Conditions: Chronic Kidney Disease Patients
• Interventions: Drug: HSK21542 Injection

• Registration Number: NCT06238388
• Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Brief Summary

This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-10
• Primary Completion: 2023-11-21
• Study First Submitted: 2024-01-21
• Study First Submitted QC: 2024-02-01
• Study First Posted: 2024-02-02
• Study Completion: 2024-02-27
• Status Verified: 2024-08
• Last Update Submitted: 2024-08-19
• Last Update Posted: 2024-08-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 6

Inclusion Criteria

1. Subjects who are willing to sign an informed consent form, fully understand the objectives and purposes of the study, and are willing to comply with the study protocol before any of the study-related procedures start.
2. Age ≥18 years old, Male or female;
3. Patients with end-stage renal diseases who receive hemodialysis (including hemodiafiltration) 3 times in a week prior to screening for at least 3 months;
4. Dry weight is 40.0-135.0 kg (inclusive) during the screening period;
5. Patients with at least two occurrences of single-compartment urea clearance (sp Kt/V) ≥ 1.2, or at least two occurrences of urea reduction ratio (URR) ≥ 65%, or one occurrence of sp Kt/V ≥ 1.2 and one occurrence of URR ≥ 65% on different days of dialysis within 6 months before administration;
6. Female of childbearing age or Male must agree to adopt efficient contraceptive measures in sexual intercourse during the study period and within 3 months after the last administration; Menopausal female subjects should have had menopause at least one year or should have had permanent sterilization (e.g., fallopian tube occlusion, hysterectomy, bilateral salpingectomy).

Exclusion Criteria

1. Expected to undergo kidney transplantation and/or parathyroidectomy during the study;

2. History of allergy to opioids, such as urticaria (Note: adverse effects related to opioid use, such as constipation and nausea, are not included as the exclusion criteria in this study);

3. Used opioids within 7 days before screening, or unable to avoid the use of opioids other than the investigational product during the study;

4. Participated in any clinical trial of other drug or medical device within 1 month before screening (received study medication or treated by the medical device in the clinical trial);

5. Used blood perfusion during the screening period or expected study period;

6. Blood pressure of upper limbs in the supine position at screening: systolic blood pressure < 90 mmHg, or diastolic blood pressure < 60 mmHg, or systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg;

7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)≥ 2.5 × upper limit of normal (ULN), or total bilirubin ≥ 2 × upper limit of normal (ULN) at screening;

8. Blood sodium > 155 mmol/L at screening;

9. Blood donation (or loss) ≥ 400 mL within the first 3 months of screening or Hemoglobin < 80 g/L at screening;

10. Positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCVAb), syphilis antibody, or human immunodeficiency virus (HIV) antibody;

11. Females who are pregnant or breastfeeding;

12. Smoking an average of more than 5 cigarettes per day within the first 3 months of screening, or not stopping the use of any tobacco products during the trial period;

13. Any physiological or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial, as judged by the study physician, including but not limited to:

    1. Known or suspected alcohol, anesthetic, or other substance abuse or drug dependence history within the first 12 months of screening; Baseline urine drug screening (if any) or positive alcohol breath test;
    2. severe systolic or diastolic heart failure within the first 6 months of screening (e.g. NYHA grade IV congestive heart failure (NYHA heart function grading criteria can be found in Appendix 3) ;
    3. Severe mental illness or cognitive impairment (e.g., dementia);
    4. Any other relevant acute or chronic neurological and psychiatric diseases (e.g., encephalopathy, coma, delirium) within 3 months before screening And the researchers believe it is not suitable for enrollment;
    5. Patients with malignant tumors, but not including: curable cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma, or any other tumor that has been cured (with no evidence of disease recurrence within 5 years).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
0.8 μg/kg HSK21542 Injection	HSK21542 Injection	0.8 μg/kg HSK21542 Injection

Primary Outcome Measures

Name	Time	Method
Cumulative recovery of unchanged drug (Ae)	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate
AUC(0-∞)	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in plasma
t1/2	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in plasma
Tmax	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in plasma
Cumulative recovery fraction of unchanged drug (Fe)	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate
Plasma clearance	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in urine, feces, and dialysate
Cmax	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in plasma
AUC(0-t)	From the start of administration to 168 hours after administration	The pharmacokinetic parameters of HSK21542 in plasma

Secondary Outcome Measures

Name	Time	Method
The main metabolites of HSK21542	From the start of administration to 168 hours after administration	The main metabolites of HSK21542 in plasma, urine, feces, and dialysate
Adverse events (AEs)	From after administration to the end of telephone follow-up	The incidence and severity of AEs

Trial Locations

Locations (1)

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital); 🇨🇳 Jinan, Shandong, China